

Final - February 18, 2016

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium

Atlanta, Georgia 30329

February 24, 2016 (1-day meeting)

<u>AGENDA ITEM</u>	<u>PURPOSE</u>	<u>PRESIDER/PRESENTER(S)</u>
Wednesday, February 24		
8:00 Welcome & Introductions		Dr. Nancy Bennett (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary; CDC)
8:15 Agency Updates CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO	Information	CDC and <i>ex officio</i> members
8:30 Human Papillomavirus (HPV) Vaccines Introduction Background: 2-dose schedules 9-valent HPV vaccine 2- vs 3-dose trial data Summary: 2-dose schedules, bivalent and quadrivalent HPV vaccines Work Group plans	Information & Discussion	Dr. Allison Kempe (ACIP, WG Chair) Dr. Lauri Markowitz (CDC/NCIRD) Dr. Alain Luxembourg (Merck) Dr. Lauri Markowitz (CDC/NCIRD) Dr. Elissa Meites (CDC/NCIRD)
9:50 Break		
10:20 Meningococcal Vaccines Introduction MenB-FHbp vaccine update Results of a mass immunization campaign with MenB-4C in Quebec, Canada Considerations for use of MenACWY vaccines in HIV-infected persons Meningococcal disease among men who have sex with men (MSM), United States, January 2012-June 2015 Considerations for use of MenACWY vaccines in MSM	Information & Discussion	Dr. Lorry Rubin (ACIP, WG Chair) Dr. Laura York (Pfizer) Dr. Gaston De Serres (Quebec, Canada) Ms. Jessica MacNeil (CDC/NCIRD) Dr. Temi Folaranmi (CDC/NCIRD) Ms. Jessica MacNeil (CDC/NCIRD)
12:10 Lunch		
1:20 Japanese Encephalitis (JE) Vaccine Introduction Duration of protection following primary series and booster dose in adults Duration of protection and need for booster dose in children JE Vaccine Work Group summary and plans	Information & Discussion	Dr. Lorry Rubin (ACIP, WG Chair) Dr. Katrin Dubischar (Valneva) Dr. Katrin Dubischar (Valneva) Dr. Susan Hills (CDC/NCEZID)
2:10 Influenza Introduction Influenza surveillance update Quadrivalent Recombinant Influenza Vaccine Influenza Vaccination and Egg Allergy Proposed Recommendations for 2016-17	Information, Discussion Vote	Dr. Ruth Karron (ACIP, WG Chair) Ms. Lynnette Brammer (CDC/NCIRD) Dr. Wayne Hachey (Protein Sciences) Dr. John Kelso (University of California, San Diego) Dr. Lisa Grohskopf (CDC/NCIRD)
3:10 Break		
3:30 Update on Zika Virus		Dr. Toby Merlin (CDC/NCEZID)

Final - February 18, 2016

3:40 Cholera Vaccine

Introduction
Vaxchora™ clinical data
Cholera Vaccine GRADE evaluation and Work Group plans

Information &
Discussion

Dr. Art Reingold (ACIP, WG Chair)
Dr. Lisa Danzig (PaxVax)
Dr. Karen Wong (CDC/NCEZID)

4:50 Vaccine Supply

Dr. Jeanne Santoli (CDC/NCIRD)

4:55 Public Comment

5:10 Adjourn

Acronyms

CDC	Centers for Disease Control & Prevention
CMS	Centers for Medicare and Medicaid Services
DoD	Department of Defense
DVA	Department of Veterans Affairs
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
LAIV	Live Attenuated Influenza Vaccine
MSM	Men who have sex with men
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	CDC National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIH	National Institutes of Health
NVPO	National Vaccine Program Office
VFC	Vaccines for Children
WG	Work Group